Monash Ivf Group Ltd · ASX:MVF
Monash Ivf — Shareholder Meeting (November 2025)
24 slides from Monash Ivf's shareholder meeting presentation, Nov 20, 2025
Slide 1: 2025 Annual General Meeting
Science. Safety. Success. 2025 Annual General Meeting 20 November 2025
Slide 2: Disclaimer
Monash IVF Group | 2025 Annual General Meeting Page 2 Disclaimer The presentation has been prepared by Monash IVF Group Limited (ACN 169 302 309) (“MVF”) (including its subsidiaries, affiliates and associated companies) and provides general background information about MVF’s activities as at the dat
Slide 3: Acknowledgement of Country
Monash IVF Group | 2025 Annual General Meeting Page 3 Acknowledgement of Country In the spirit of reconciliation, Monash IVF acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their Elders past and present a
Slide 4: Chairman's Address
Monash IVF Group | 2025 Annual General Meeting Page 4 Chairman’s Address Mr. Richard Davis
Slide 5: Agenda
Monash IVF Group | 2025 Annual General Meeting Page 5 Agenda • Chairman’s Address • Acting Chief Executive Officer Address • Voting Instructions • How to Ask a Question • Business of the AGM • Questions • Meeting close
Slide 6: Voting instructions
Monash IVF Group | 2025 Annual General Meeting Page 6 Voting instructions 1. Click the Get a Voting Card box on your screen 2. Enter your Shareholder or Proxy Details and click Submit Details and Vote 3. When the Voting Card pops up, select either Full Vote or Partial Vote 4. Select your voting pref
Slide 7: How to Ask a Question
Monash IVF Group | 2025 Annual General Meeting Page 7 How to Ask a Question 1. In person at the meeting 2. Virtually o Click the Ask a Question box on your screen o Select the Item of Business your question relates to o Type your question in the space provided* o Click Submit Question *Please note,
Slide 8: Year in Review
Monash IVF Group | 2025 Annual General Meeting Page 8 Year in Review
Slide 9: Vision 2026
Monash IVF Group | 2025 Annual General Meeting Page 9 Vision 2026 Best in class fertility solutions, diagnostics, genetics and pathology.
Slide 10: Sustainability Strategy
Monash IVF Group | 2025 Annual General Meeting Page 10 Sustainability Strategy We have summarized our Sustainability Strategy on a page to highlight the key areas of focus where Monash IVF Group can achieve the maximum impact in delivering, safe, effective healthcare services, that give every person
Slide 11: Chairman's Address: Thank you.
Monash IVF Group | 2025 Annual General Meeting Page 11 Chairman’s Address Thank you.
Slide 12: Acting Chief Executive Officer's Address
Monash IVF Group | 2025 Annual General Meeting Page 12 Acting Chief Executive Officer’s Address Mr. Malik Jainudeen
Slide 13: FY25 Financial Overview
Monash IVF Group | 2025 Annual General Meeting Page 13 FY25 Financial Overview • Underlying NPAT(1)(2)(3) of $27.4m, down by 8.1% (in line with updated guidance provided in May 2025); • 6.7% growth in Revenue to $271.9m; • 5.6% growth in Underlying EBITDA(1)(2) to $66.3m; • FY25 Reported NPAT(3) of
Slide 14: FY25 Operational Overview
Monash IVF Group | 2025 Annual General Meeting Page 14 FY25 Operational Overview Domestic IVF • Monash IVF FY25 Australian Stimulated Cycles(1) decreased by 5.0% compared to pcp (>90% of the decline related to VIC); • Monash IVF FY25 Frozen Embryo Transfer cycles(2) increased by 7.1%; • Australian I
Slide 15: FY25 Operational Updates: Domestic IVF
Monash IVF Group | 2025 Annual General Meeting Page 15 FY25 Operational Updates: Domestic IVF • Continually enhancing our doctor value proposition to retain and attract doctors; • Net increase of 3 new fertility specialists in FY25; • 11 new fertility specialists joined; 8 departures (largely retire
Slide 16: Leading science and technology driving pregnancy rates to >40%
Monash IVF Group | 2025 Annual General Meeting Page 16 Leading science and technology driving pregnancy rates to >40% 40.3% Clinical pregnancy rate per embryo Examples of current investments in innovative technology transferred to drive success rates and improve patient outcome (women aged <43 years
Slide 17: Matcher Electronic Witnessing System roll-out complete
Monash IVF Group | 2025 Annual General Meeting Page 17 Matcher® Electronic Witnessing System roll-out compete Roll-out of Matcher® Electronic Witnessing across all Australian Monash IVF Group laboratories was completed during FY25 • Matcher® is a proven electronic witnessing system used by IVF clini
Slide 18: FY25 Operational Updates: Diagnostics
Monash IVF Group | 2025 Annual General Meeting Page 18 FY25 Operational Updates: Diagnostics Ultrasound • FY25 scan volumes decreased by 0.4% on pcp; • Strong scan volume growth in MUFW (Melbourne) offset by decrease in scan volumes in SUFW (Sydney); Genetics • FY25 PGT-M cycles were down by 9% in F
Slide 19: FY25 Operational Updates: International IVF
Monash IVF Group | 2025 Annual General Meeting Page 19 FY25 Operational Updates: International IVF • Soft 2H25 volume performances across KL Fertility, Johor Bahru and Singapore; offsetting the 8% volume growth in 1H25; • International Stimulated cycles decreased by 6.4% in FY25; • FY25 Internationa
Slide 20: FY26 Priorities
Monash IVF Group | 2025 Annual General Meeting Page 20 FY26 Priorities Doctor Retention and IVF Fundamentals Integrated Consolidate Asia Acquisition and Conversion Diagnostics Strategy Focus Ultrasound, Genetics & Pathology Risk and Governance Drive High Digital Vision 2030 Enhancements Performance
Slide 21: YTD Trading update
Monash IVF Group | 2025 Annual General Meeting Page 21 YTD Trading update Australian ARS Business • MVF STIM cycles to October YTD declined by 12% compared to pcp. • Australian ARS Sector STIM cycles to September YTD1 declined by 0.6% vs. pcp. • MVF market share to September YTD1 was down by 2.4% on
Slide 22: Outlook and 1H26 guidance
Monash IVF Group | 2025 Annual General Meeting Page 22 Outlook and 1H26 guidance 1H26 Underlying NPAT1 expected to be between $10m-10.5m. FY26 Underlying NPAT1 is now expected to be at the bottom end of the $20m-23m range. • Reflects ongoing softness in Australian stimulated cycle volumes and New IV
Slide 23: Voting instructions
Monash IVF Group | 2025 Annual General Meeting Page 23 Voting instructions
Slide 24: Slide 24
Monash IVF Group — Shareholder Meeting (November 2025) on 6ix